$NNVC
NANOVIRICIDES, INC. Stock $nnvc

$nnvc Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-Q Financial Statement

#000114420418030083 Filed on May 21, 2018

Income Statement

Concept	2018 Q1	2017 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.390M	$1.060M
YoY Change	31.13%	8.16%
% of Gross Profit
Research & Development	$1.291M	$1.559M
YoY Change	-17.18%	46.06%
% of Gross Profit
Depreciation & Amortization	$168.5K	$163.6K
YoY Change	2.96%	0.06%
% of Gross Profit
Operating Expenses	$2.418M	$2.616M
YoY Change	-7.55%	145.03%
Operating Profit	-$2.418M	-$2.616M
YoY Change	-7.55%
Interest Expense	$310.0K	$110.0K
YoY Change	181.82%	-63.47%
% of Operating Profit
Other Income/Expense, Net	$308.3K	-$523.0K
YoY Change	-158.95%	-82.23%
Pretax Income	-$2.110M	-$3.139M
YoY Change	-32.78%	-37.12%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.110M	-$3.139M
YoY Change	-32.78%	-37.12%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.03
Diluted Earnings Per Share	-$659.4K	-$0.05
COMMON SHARES
Basic Shares Outstanding	64.07M shares	61.00M shares
Diluted Shares Outstanding	64.07M shares	61.00M shares

Balance Sheet

Concept	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.62M	$16.16M
YoY Change	-34.28%	-36.88%
Cash & Equivalents	$10.62M	$16.16M
Short-Term Investments
Other Short-Term Assets	$330.0K	$590.0K
YoY Change	-44.07%	90.32%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$10.95M	$16.74M
YoY Change	-34.59%	-35.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.99M	$11.39M
YoY Change	-3.51%	-4.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$20.00K	$60.00K
YoY Change	-66.67%	-50.0%
Total Long-Term Assets	$11.39M	$11.84M
YoY Change	-3.8%	-4.57%
TOTAL ASSETS
Total Short-Term Assets	$10.95M	$16.74M
Total Long-Term Assets	$11.39M	$11.84M
Total Assets	$22.34M	$28.58M
YoY Change	-21.83%	-25.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.880M	$110.0K
YoY Change	1609.09%	-75.56%
Accrued Expenses	$410.0K	$50.00K
YoY Change	720.0%	-36.2%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.190M	$330.0K
YoY Change	866.67%	-95.01%
LONG-TERM LIABILITIES
Long-Term Debt	$4.730M	$3.730M
YoY Change	26.81%	26.01%
Other Long-Term Liabilities	$0.00	$2.110M
YoY Change	-100.0%	-55.67%
Total Long-Term Liabilities	$4.730M	$5.840M
YoY Change	-19.01%	-24.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.190M	$330.0K
Total Long-Term Liabilities	$4.730M	$5.840M
Total Liabilities	$3.190M	$6.170M
YoY Change	-48.3%	-56.96%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.15M	$22.41M
YoY Change
Total Liabilities & Shareholders Equity	$22.34M	$28.58M
YoY Change	-21.83%	-25.42%

Cashflow Statement

Concept	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$2.110M	-$3.139M
YoY Change	-32.78%	-37.12%
Depreciation, Depletion And Amortization	$168.5K	$163.6K
YoY Change	2.96%	0.06%
Cash From Operating Activities	-$1.300M	-$2.050M
YoY Change	-36.59%	-20.54%
INVESTING ACTIVITIES
Capital Expenditures	-$140.0K	-$100.0K
YoY Change	40.0%	66.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$140.0K	-$100.0K
YoY Change	40.0%	66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-1.000M
YoY Change	-100.0%
NET CHANGE
Cash From Operating Activities	-1.300M	-2.050M
Cash From Investing Activities	-140.0K	-100.0K
Cash From Financing Activities	0.000	-1.000M
Net Change In Cash	-1.440M	-3.150M
YoY Change	-54.29%	19.32%
FREE CASH FLOW
Cash From Operating Activities	-$1.300M	-$2.050M
Capital Expenditures	-$140.0K	-$100.0K
Free Cash Flow	-$1.160M	-$1.950M
YoY Change	-40.51%	-22.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1028938	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1559202	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3472193	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3081442	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	2418267	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	2615714	USD
	us-gaap	Operating Expenses OperatingExpenses	7042494	USD
	us-gaap	Operating Expenses OperatingExpenses	7353781	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2418267	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2615714	USD
	us-gaap	Depreciation Depreciation	501378	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	6202	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2177	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6888480	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4256419	USD
CY2018Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-332524	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1348247	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-332524	USD
	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	359214	USD
	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	1124411	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1676093	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1949686	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2109962	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3138677	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6912411	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7746520	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-2109962	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-3138677	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6912411	USD
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64068378	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61002941	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63566719	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59115786	shares
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64068378	shares
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61002941	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63566719	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59115786	shares
CY2018Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	23769	USD
CY2017Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	17959	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	73133	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	43870	USD
CY2018Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2017Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	165767	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	185275	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	655767	USD
	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	81000	USD
	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices	14382	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	196895	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	180466	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	118620	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24162185	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16155085	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	359214	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1124411	USD
	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	1949686	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	142746	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8007100	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4481624	USD
	us-gaap	Interest Paid Net InterestPaidNet	492434	USD
	us-gaap	Interest Paid Net InterestPaidNet	166667	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	14382	USD
	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	443920	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-41786	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-37752	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	59754	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	16182	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	1348168	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-767454	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	372800	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	16668	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-41667	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-125001	USD
	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-60274	USD
	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-440512	USD
	us-gaap	Business Acquisition Date Of Acquisition Agreement1 BusinessAcquisitionDateOfAcquisitionAgreement1	2005-05-12
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6662428	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6958162	shares
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6912411	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7746520	USD
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.11
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.13
CY2017Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7996402	USD
CY2018Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	8011230	USD
CY2017Q2	nnvc	Office Equipment Gross OfficeEquipmentGross	48486	USD
CY2018Q1	nnvc	Office Equipment Gross OfficeEquipmentGross	57781	USD
CY2017Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	5607	USD
CY2018Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	5607	USD
CY2017Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5466066	USD
CY2018Q1	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5667148	USD
CY2018Q1	us-gaap	Land Land	260000	USD
CY2017Q2	us-gaap	Land Land	260000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	168457	USD
CY2017Q1	us-gaap	Depreciation Depreciation	163611	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2013Q3	nnvc	Warrants Issued WarrantsIssued	2945428	shares
CY2014Q1	nnvc	Warrants Issued WarrantsIssued	2479935	shares
CY2013Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2810071	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2479935	shares
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2018Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5300000	USD
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68985375	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63306774	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68985375	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63306774	shares
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	308305	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-522963	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	130083	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-392739	USD
	us-gaap	Business Acquisition Name Of Acquired Entity BusinessAcquisitionNameOfAcquiredEntity	Edot-com.com, Inc
	nnvc	Stock Issued During Period Value Issued For Series C Debentures StockIssuedDuringPeriodValueIssuedForSeriesCDebentures	4730000	USD
	dei	Entity Incorporation State Country Name EntityIncorporationStateCountryName	Colorado
	nnvc	Adjustments To Additional Paid In Capital Warrant Issued As Severance Payment AdjustmentsToAdditionalPaidInCapitalWarrantIssuedAsSeverancePayment	53500	USD
	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	33750	USD
	nnvc	Series Preferred Shares Issued For Debenture Interest SeriesPreferredSharesIssuedForDebentureInterest	314343	USD
	nnvc	Warrants Issued For Severance Agreement WarrantsIssuedForSeveranceAgreement	53500	USD
	nnvc	Warrants Issued For Severance Agreement WarrantsIssuedForSeveranceAgreement		USD
	nnvc	Gains Losses On Extinguishment Of Series C Debenture GainsLossesOnExtinguishmentOfSeriesCDebenture	-1348247	USD
	nnvc	Gains Losses On Extinguishment Of Series C Debenture GainsLossesOnExtinguishmentOfSeriesCDebenture	0	USD
	nnvc	Loss On Extinguishment Of Series B Debenture LossOnExtinguishmentOfSeriesBDebenture	0	USD
	nnvc	Loss On Extinguishment Of Series B Debenture LossOnExtinguishmentOfSeriesBDebenture	-332524	USD
	nnvc	Increase Decrease In Prepaid Expenserelated Party IncreaseDecreaseInPrepaidExpenserelatedParty	0	USD
	nnvc	Increase Decrease In Prepaid Expenserelated Party IncreaseDecreaseInPrepaidExpenserelatedParty	370187	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1000000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	4605000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	nnvc	Preferred Stock Issued For Debentures PreferredStockIssuedForDebentures	314343	USD
	nnvc	Preferred Stock Issued For Debentures PreferredStockIssuedForDebentures	0	USD
	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	costs (direct and indirect) plus no more than 30% of a certain portion of direct costs
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	5000000	USD
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2000	USD
CY2017	nnvc	Net Proceeds From Issuance Of Debt NetProceedsFromIssuanceOfDebt	1968275	USD
	us-gaap	Stock Issued1 StockIssued1	125000	USD
	us-gaap	Stock Issued1 StockIssued1	83334	USD
CY2018Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	77492	USD
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	122555	USD
CY2018Q1	nnvc	Share Price As Per Redemption Agreement SharePriceAsPerRedemptionAgreement	0.0100	pure
CY2018Q1	nnvc	Unpaid Deferred Interest UnpaidDeferredInterest	125000	USD
CY2017Q4	nnvc	Net Proceeds From Issuance Of Debt NetProceedsFromIssuanceOfDebt	1968275	USD
CY2018Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	902426	USD
CY2017Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2018Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	118851	USD
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	819994	USD
	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	65716	USD
CY2018Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	150000	USD
CY2018Q1	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	4730000	USD
CY2018Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4730000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Note 1 - Organization and Nature of Business</font></font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">NanoViricides, Inc. (the “Company”) was incorporated under the laws of the State of Colorado on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">July 25, 2000</font> as Edot-com.com, Inc<b>.</b> which was organized for the purpose of conducting internet retail sales. On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling as a Nevada corporation. On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 12, 2005</font>, the corporations were merged and Edot-com.com, Inc<b>.,</b> the Nevada corporation, became the surviving entity.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired NanoViricides, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”). NanoViricides, Inc. was incorporated under the laws of the State of Florida on May 12, 2005.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80,000,000</font> newly issued shares of ECMM common stock resulting in an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000,000</font> shares of ECMM common stock issued and outstanding. NVI then became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI shareholders on a pro rata basis, on the basis of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000</font></font> shares of the Company’s Common Stock for each share of NVI common stock held by such NVI shareholder at the time of the Exchange</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As a result of the Exchange transaction, the former NVI stockholders held approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80</font>% of the voting capital stock of the Company immediately after the Exchange.  For financial accounting purposes, this acquisition was a reverse acquisition of ECMM by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NVI.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased.  Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. NanoViricides is unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinical trials. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="justify">We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV-1 and HSV-2), Influenza and Asian Bird Flu Virus. Under the License Agreements, TheraCour Pharma will receive a royalty upon sale of resulting products from NanoViricides. There is no royalty payable to date. The Company has declared its intent to license VZV (shingles) and the remaining human herpesviruses from TheraCour, and has conducted a valuation for the shingles and PHN indications. The Company intends to complete the negotiations after the appointment of a new Chief Executive Officer. The search for a new CEO with appropriate pharmaceutical industry background is ongoing and the Company is performing due diligence on the final candidates at this time.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <font style="FONT-SIZE: 10pt"> </font> <font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On February 15, 2010 the Company executed an Additional License Agreement with TheraCour.  Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to 2,000,000 shares (adjusted for the 3.5 to 1 reverse split) of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”).  The Series A Preferred Stock is convertible, only in the event of a “change of control” of the Company, as defined in the designation of Series A Preferred Stock (see Note 2 for further details), into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.  The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Series A Preferred Stock do not contain any rights to dividends, have no liquidation preference, and are not to be amended without the Holder’s approval. The <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares were valued at the par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000</font>.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company has declared its intent to license VZV (shingles) and the remaining human herpesviruses from TheraCour, and has conducted a valuation for the shingles and PHN indications recently. The Company intends to complete the negotiations after the appointment of a new Chief Executive Officer.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company’s search for a new CEO with strong pharmaceutical industry background has been accelerated after Dr. Seymour’s retirement at the end of January 2018. The Executive Search Committee is currently performing due diligence on the final candidates. In the interim, the Board has appointed Anil R. Diwan, PhD, President and Chairman, as the acting CEO in January, following retirement of Dr. Eugene Seymour. His appointment as interim CEO has provided the Company with a continuous leadership. Dr. Diwan and Dr. Seymour together constituted the Executive Committee, and thus, Dr. Diwan has been involved in strategic decision-making, as well as fund-raising activities since the founding of the Company.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Forfeited SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueForfeited	0	USD
	nnvc	Compensation Revised In Respective Of Shares CompensationRevisedInRespectiveOfShares	75000	shares

Files In Submission

Name	View Source	Status
0001144204-18-030083-index-headers.html	Edgar Link	pending
0001144204-18-030083-index.html	Edgar Link	pending
0001144204-18-030083.txt	Edgar Link	pending
0001144204-18-030083-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nnvc-20180331.xml	Edgar Link	completed
nnvc-20180331.xsd	Edgar Link	pending
nnvc-20180331_cal.xml	Edgar Link	unprocessable
nnvc-20180331_def.xml	Edgar Link	unprocessable
nnvc-20180331_lab.xml	Edgar Link	unprocessable
nnvc-20180331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv492966_10q.htm	Edgar Link	pending
tv492966_ex31-1.htm	Edgar Link	pending
tv492966_ex31-2.htm	Edgar Link	pending
tv492966_ex32-1.htm	Edgar Link	pending
tv492966_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NNVC
NANOVIRICIDES, INC. Stock $nnvc

2018 Q1 Form 10-Q Financial Statement

#000114420418030083 Filed on May 21, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC NANOVIRICIDES, INC. Stock $nnvc

2018 Q1 Form 10-Q Financial Statement

#000114420418030083 Filed on May 21, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC
NANOVIRICIDES, INC. Stock $nnvc